After entry of the instant amendment, the claims pending in this application will read as follows:

16. A method for treating or preventing allergy in a patient suffering from a cedar pollen allergy, the method comprising:

(a) identifying an HLA class II molecule expressed by the patient;

(b) selecting an antigenic peptide derived from Japanese cedar pollen allergen Cry j 1 or Japanese cedar pollen allergen Cry j 2, wherein the antigenic peptide binds to the HLA class II molecule and wherein:

(1) if the HLA class II molecule identified in step (a) is DQA1*0102-DQB1*0602, the antigenic peptide is selected from the group consisting of SEQ ID NO:1, 5, 7, 9, 10, 21, 23 and 25;

(2) if the HLA class II molecule identified in step (a) is DPA1*0101-DPB1*0501, the antigenic peptide is selected from the group consisting of SEQ ID NO:2, 8, and 15;

(3) if the HLA class II molecule identified in step (a) is DPA1*0101-DPB1*0201, the antigenic peptide is SEQ ID NO:17;

(4) if the HLA class II molecule identified in step (a) is DPA1*0202-DQB1*0501, the antigenic peptide is SEQ ID NO:22;

(5) if the HLA class II molecule identified in step (a) is DRB5*0101, the antigenic peptide is selected from the group consisting of SEQ ID NO:3, 4, 14, and 19;

(6) if the HLA class II molecule identified in step (a) is DRB1*0901, the antigenic peptide is selected from the group consisting of SEQ ID NO:6, 7, 12, 16, and 20;

(7) if the HLA class II molecule identified in step (a) is DRB4*0101, the antigenic peptide is selected from the group consisting of SEQ ID NO:7, 12, and 18;

(8) if the HLA class II molecule identified in step (a) is DRB1*1501, the antigenic peptide is selected from the group consisting of SEQ ID NO:13 and 19; and

(c) administering the selected antigenic peptide to the patient.

17. A customized pharmaceutical composition for treating a patient suffering from a cryptomeria pollen allergy, the composition comprising:

(a) an effective amount of an antigenic peptide derived from Japanese cedar pollen allergen Cry j 1 or Japanese cedar pollen allergen Cry j 2, wherein the antigenic peptide binds to an HLA class II molecule expressed by the patient and wherein:

(1) if the patient expresses HLA class II molecule DQA1*0102-DQB1*0602, the antigenic peptide is selected from the group consisting of SEQ ID NO:1, 5, 7, 9, 10, 21, 23 and 25;

(2) if the patient expresses HLA class II molecule DPA1*0101-DPB1*0501, the antigenic peptide is selected from the group consisting of SEQ ID NO:2, 8, and 15;

(3) if the patient expresses HLA class II molecule DPA1*0101-DPB1*0201, the antigenic peptide is SEQ ID NO:17;

(4) if the patient expresses HLA class II molecule DPA1*0202-DQB1*0501, the antigenic peptide is SEQ ID NO:22;

(5) if the patient expresses HLA class II molecule DRB5*0101, the antigenic peptide is selected from the group consisting of SEQ ID NO:3, 4, 14, and 19;

(6) if the patient expresses HLA class II molecule DRB1*0901, the antigenic peptide is selected from the group consisting of SEQ ID NO:6, 7, 12, 16, and 20;

(7) if the patient expresses HLA class II molecule DRB4*0101, the antigenic peptide is selected from the group consisting of SEQ ID NO:7, 12, and 18;

(8) if the patient expresses HLA class II molecule DRB1*1501, the antigenic peptide is selected from the group consisting of SEQ ID NO:13 and 19; and

(b) a pharmaceutically acceptable diluent or carrier.